Additionally, glycogen synthase kinase 3β (GSK3β) and CC chemokine receptor 6 (CCR6) have been identified as upstream positive regulators of TAFRO syndrome, which could serve as both diagnostic markers and therapeutic targets for TAFRO syndrome (20). This evidence concerns the gene CCR6 and Castleman-Kojima disease.